Cost-Effectiveness Analysis of Diagnostic Tests for Para-Aortic Lymph Node Detection in Locally Advanced Cervical Cancer

References

• International Agency for Research on Cancer; 2018. Available from: http://globocan.iarc.fr. Accessed October 8, 2018.
   Google Scholar
• Gakidou E, Nordhagen S, Obermeyer Z. Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS Med. 2008;5:e132. doi:10.1371/journal.pmed.0050132
   PubMed Web of Science ®Google Scholar
• Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. FIGO cancer report 2018. Cancer of the cervix uteri. Int J Gynecol Obstet. 2018;143(Suppl. 2):22–36. doi:10.1002/ijgo.12611
   PubMed Web of Science ®Google Scholar
• Berman ML, Keys H, Creasman W, Disaia P, Bundy B, Blessing J. Survival and patterns of recurrence in cervical cancer metastatic to periaortic lymph nodes (a Gynecologic Oncology Group study). Gynecol Oncol. 1984;19:8–16. doi:10.1016/0090-8258(84)90151-3
   PubMed Web of Science ®Google Scholar
• Piver MS, Barlow JJ. Para‐aortic lymphadenectomy in staging patients with advanced local cervical cancer. Obstet Gynecol. 1974;43:544–548.
   Web of Science ®Google Scholar
• Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group study. J Clin Oncol. 1999;17:1339–1348. doi:10.1200/JCO.1999.17.5.1339
   PubMed Web of Science ®Google Scholar
• Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340:1144–1153. doi:10.1056/NEJM199904153401502
   PubMed Web of Science ®Google Scholar
• Lanciano R, Calkins A, Bundy BN, et al. Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study. J Clin Oncol. 2005;23:8289–8295. doi:10.1200/JCO.2004.00.0497
   PubMed Web of Science ®Google Scholar
• Capozzi VA, Sozzi G, Monfardini L, et al. Transperitoneal versus extraperitoneal laparoscopic aortic lymph nodal staging for locally advanced cervical cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2021;47:2256–2264.
   Web of Science ®Google Scholar
• Negra˜o MV, Silva Lima JM, Severino Silva SC, Estevez Diz MDP, Costa Miranda V. Management of para-aortic lymph node disease in patients with cervical cancer. What is the best approach? Int J Gynecol Cancer. 2017;27:543–549. doi:10.1097/IGC.0000000000000914
   Web of Science ®Google Scholar
• Hwang L, Bailey A, Lea J, Albuquerque K. Para-aortic nodal metastases in cervical cancer: a blind spot in the International Federation of Gynecology and Obstetrics staging system: current diagnosis and management. Future Oncol. 2015;11:309–322. doi:10.2217/fon.14.200
   Web of Science ®Google Scholar
• Lai CH, Huang KG, Hong JH, et al. Randomized trial of surgical staging (extraperitoneal or laparoscopic) versus clinical staging in locally advanced cervical cancer. Gynecol Oncol. 2003;89:160–167. doi:10.1016/S0090-8258(03)00064-7
   PubMed Web of Science ®Google Scholar
• Jang H, Chun M, Cho O, Heo JS, Ryu HS, Chang SJ. Prognostic factors and treatment outcome after radiotherapy in cervical cancer patients with isolated para-aortic lymph node metastases. J Gynecol Oncol. 2013;24:229–235. doi:10.3802/jgo.2013.24.3.229
   PubMed Web of Science ®Google Scholar
• Stryker JA, Mortel R. Survival following extended field irradiation in carcinoma of cervix metastatic to para-aortic lymph nodes. Gynecol Oncol. 2000;79:399–405. doi:10.1006/gyno.2000.5977
   Web of Science ®Google Scholar
• Shim SH, Kim DYK, Lee SJ, et al. Prediction model for para-aortic lymph node metastasis in patients with locally advanced cervical cancer. Gynecol Oncol. 2017;144:40–45. doi:10.1016/j.ygyno.2016.11.011
   Web of Science ®Google Scholar
• Kim YS, Kim JH, Ahn SD, et al. High-dose extended-field irradiation and high-dose-rate brachytherapy with concurrent chemotherapy for cervical cancer with positive para-aortic lymph nodes. Int J Radiat Oncol Biol Phys. 2009;74:1522–1528. doi:10.1016/j.ijrobp.2008.10.024
   Web of Science ®Google Scholar
• Jung J, Park G, Kim YS. Definitive extended-field intensity-modulated radiotherapy with chemotherapy for cervical cancer with para-aortic nodal metastasis. Anticancer Res. 2014;34:4361–4366.
   Web of Science ®Google Scholar
• Yoon HI, Cha J, Keum KC, et al. Treatment outcomes of extended-field radiation therapy and the effect of concurrent chemotherapy on uterine cervical cancer with para-aortic lymph node metastasis. Radiat Oncol. 2015;10:18. doi:10.1186/s13014-014-0320-5
   Web of Science ®Google Scholar
• Marnitz S, Schram J, Budach V, et al. Extended field chemoradiation for cervical cancer patients with histologically proven para-aortic lymph node metastases after laparoscopic lymphadenectomy. Strahlenther Onkol. 2015;191:421–428. doi:10.1007/s00066-014-0785-z
   Web of Science ®Google Scholar
• Small W, Winter K, Levenback C, et al. Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of ARM 1 of RTOG 0116. Int J Radiat Oncol Biol Phys. 2007;68:1081–1087. doi:10.1016/j.ijrobp.2007.01.026
   Web of Science ®Google Scholar
• Rotman M, Pajak TF, Choi K, et al. Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten-year treatment results of RTOG 79–20. JAMA. 1995;274:387–393. doi:10.1001/jama.1995.03530050035029
   PubMed Web of Science ®Google Scholar
• Whitley NO, Brenner DE, Francis A, et al. Computed tomographic evaluation of carcinoma of the cervix. Radiology. 1982;142:439–446. doi:10.1148/radiology.142.2.7054834
   PubMed Web of Science ®Google Scholar
• Kitagawa R, Katsumata K, Shibata T, et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open label randomized phase III trial (JCOG0505). J Clin Oncol. 2015;33:2129–2135. doi:10.1200/JCO.2014.58.4391
   PubMed Web of Science ®Google Scholar
• Liu B, Gao S, Li S. A comprehensive comparison of CT, MRI, Positron Emission Tomography or Positron Emission Tomography/CT, and diffusion weighted imaging-MRI for detecting the lymph nodes metastases in patients with cervical cancer: a meta-analysis based on 67 studies. Gynecol Obstet Invest. 2017;82:209–222. doi:10.1159/000456006
   Web of Science ®Google Scholar
• Katanyoo K, Tangjitgamol S, Chongthanakorn M, et al. Treatment outcomes of concurrent weekly carboplatin with radiation therapy in locally advanced cervical cancer patients. Gynecol Oncol. 2011;123:571–576. doi:10.1016/j.ygyno.2011.09.001
   PubMed Web of Science ®Google Scholar
• Pearcey R, Brundage M, Drouin P, et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol. 2002;20:966–972. doi:10.1200/JCO.2002.20.4.966
   PubMed Web of Science ®Google Scholar
• Life table by country-Thailand; 2020. Available from: https://apps.who.int/gho/data/view.main.61640?lang=en. Accessed February 29, 2020.
   Google Scholar
• Riewpaiboon A. Cost analysis. In: Chaikledkaew U, Teerawattananon Y, editors. Thai National Health Technology Assessment Guidelines. 2nd ed. Nonthaburi: Watcharin PP; 2013:23–42.
   Google Scholar
• Permsuwan U, Guntawongwan K, Buddhawongsa P. Handling time in economic evaluation studies. J Med Assoc Thai. 2014;97(Suppl 5):S50–8.
   PubMedGoogle Scholar
• Pattanaphesaj J, Thavorncharoensap M, Ramos-Goñi JM, Tongsiri S, Ingsrisawang L, Teerawattananon Y. The EQ-5D-5L Valuation study in Thailand. Expert Rev Pharmacoecon Outcomes Res. 2018;18:551–558. doi:10.1080/14737167.2018.1494574
   PubMed Web of Science ®Google Scholar
• Lee JY, Kim Y, Lee TJ, et al. Cost-effectiveness of para-aortic lymphadenectomy before chemoradiotherapy in locally advanced cervical cancer. J Gynecol Oncol. 2015;26:171–178. doi:10.3802/jgo.2015.26.3.171
   Web of Science ®Google Scholar
• Rajan N, Barraclough H, Puri T, Orlando M. Cost effectiveness of concurrent gemcitabine and cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in stages IIB-IVA cervical cancer. Gynecol Oncol Rep. 2014;10:36–37. doi:10.1016/j.gore.2014.09.002
   Google Scholar
• Kim H, Rajagopalan MS, Beriwal S, Huq MS, Smith KJ. Cost-effectiveness analysis of 3D image-guided brachytherapy compared with 2D brachytherapy in the treatment of locally advanced cervical cancer. Brachytherapy. 2015;14:29–36. doi:10.1016/j.brachy.2014.09.002
   Web of Science ®Google Scholar
• Chai Y, Wang J, Wang T, et al. Cost-effectiveness of radical hysterectomy with adjuvant radiotherapy versus radical radiotherapy for FIGO stage IIB cervical cancer. Onco Targets Ther. 2016;9:349–354. doi:10.2147/OTT.S90798
   Web of Science ®Google Scholar
• Perdrizet J, D’Souza D, Skliarenko J, et al. A cost-utility analysis of magnetic resonance (MR) guided brachytherapy versus two-dimensional and computed tomography (CT) guided brachytherapy for locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2020;107:512–521. doi:10.1016/j.ijrobp.2020.03.004
   Web of Science ®Google Scholar
• Lesnock JL, Farris C, Beriwal S, Krivak TC. Upfront treatment of locally advanced cervical cancer with intensity modulated radiation therapy compared to four-field radiation therapy: a cost-effectiveness analysis. Gynecol Oncol. 2013;129:574–579. doi:10.1016/j.ygyno.2013.02.012
   Web of Science ®Google Scholar
• Konski A, Watkins-Bruner D, Feigenberg S, et al. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys. 2006;66:408–415. doi:10.1016/j.ijrobp.2006.04.049
   PubMed Web of Science ®Google Scholar
• Jewell EL, Smrtka M, Broadwater MS, et al. Utility scores and treatment preferences for clinical early stage cervical cancer. Value Health. 2011;14:582–586. doi:10.1016/j.jval.2010.11.017
   Web of Science ®Google Scholar
• El-Gazzaz G, Hull TL, Mignanelli E, Hammel J, Gurland B, Zutchi M. Obstetric and cryptoglandular rectovaginal fistulas: long-term surgical outcome, quality of life, and sexual function. J Gastrointest Surg. 2010;14:1758–1763. doi:10.1007/s11605-010-1259-y
   Web of Science ®Google Scholar
• Ernst EJ, Ernst ME, Hoehns J, Bergus GR. Women’s QOL is decreased by acute cystitis and antibiotic adverse effects associated with treatment. Health Qual Life Outcomes. 2005;3:45. doi:10.1186/1477-7525-3-45
   PubMedGoogle Scholar